title: Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin.
authors.forename: W S
authors.initials: WS
authors.lastname: Fletcher
authors.forename: E A
authors.initials: EA
authors.lastname: Woltering
authors.forename: H S
authors.initials: HS
authors.lastname: Moseley
authors.forename: G
authors.initials: G
authors.lastname: Bos
authors.forename: L
authors.initials: L
authors.lastname: Lebredo
authors.forename: D
authors.initials: D
authors.lastname: Brown
authors.forename: K
authors.initials: K
authors.lastname: Small
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005121:Extremities; D006801:Humans; D006979:Hyperthermia, Induced; D015994:Incidence; D008545:Melanoma / Q000188:drug therapy / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy / Q000628:therapy*; D012206:Rhabdomyolysis / Q000139:chemically induced; D012878:Skin Neoplasms / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D003609:Dactinomycin; D003606:Dacarbazine; D002945:Cisplatin; D008558:Melphalan